GAVI S VACCINE INVESTMENT STRATEGY

Size: px
Start display at page:

Download "GAVI S VACCINE INVESTMENT STRATEGY"

Transcription

1 GAVI S VACCINE INVESTMENT STRATEGY Judith Kallenberg, Head of Policy PDVAC 22 June 2017, Geneva Reach every child

2 Gavi finances vaccines and immunisation through three routes ($9 Billion in ) Health Systems and Immunisation Strengthening Vaccines Technical assistance VIS Innovation 2

3 Gavi, the Vaccine Alliance, mission: To save children s lives and protect people s health by increasing equitable use of vaccines in lower income countries 3

4 Gavi supports 73 countries, reaching ~80 million children per year Since 2000: 600,000,000 children immunized 8,000,000 future deaths averted

5 Gavi s vaccine portfolio has diversified over time Pentavalent HPV RI Uptake of vaccines in RI/mass preventive campaigns Hepatitis B Hib YF routine PCV Rotavirus Measles 2 nd dose YF campaigns Typhoid JE Measles rubella Men A RI/MPC Measles campaigns YF campaigns HPV multi-age cohort JE routine Outbreak response YF stockpile Meningitis stockpile Measles outbreak response Cholera Ebola Learning agenda Rabies Malaria Elimination/ eradication Year of investment decision IPV

6 Vaccine investments increasingly targeted at specific sets of countries Universal* Pentavalent Hepatitis B Hib PCV Rotavirus Measles 2 nd dose HPV RI Measles rubella Meningitis A RI/MPC IPV HPV multi-age cohort Targeted* Yellow Fever (YF) routine YF campaigns Typhoid JE Measles campaigns YF campaigns Other* YF stockpile Meningitis stockpile Measles outbreak response Rabies Cholera Malaria Ebola Year of investment decision *Universal: all Gavi countries; Targeted: focused on sub-set of GAVI countries; Other: outbreak response, learning agenda

7 VIS is aligned with Gavi s strategic cycle and financial replenishment Strategic period Strategic period VIS #1 MenA, JE, HPV Rubella, Typhoid conjugate VIS #2 YF mass campaigns, Cholera stockpile, Rabies/cholera studies, Malaria deferred RTS,S pilot funding decision VIS #3 7

8 A robust and evidence-based process will be conducted over the next 18 months Km 2: What is the appropriate vaccination strategy? Km 3: What is the demand in Gavi countries? Km 4: Would it be feasible and what would it cost? Km 5: What would be the impact? Km 6: How does it compare to other potential investments and current portfolio? EXIT Final Investment Decisions 8 Km 1: What is burden of disease? Oct 2017: decision framework(s) May 2018: shortlist Oct 2018: vaccine investment decisions

9 VIS

10 WHO landscape analysis: the starting point Vaccines already licensed, not on GAVI list Vaccines that might be licensed by 2023 Incremental changes to existing policy or vaccines 10

11 Preliminary list to be further reviewed: Dengue Hepatitis A Hepatitis E Influenza seasonal, maternal (pandemic?) Malaria (refresh with no decision in 2018) Mening CYWX Mumps/MMR Rabies, Rabies Ig/mAb Typhoid RSV (& RSV mab?) Group B strep OCV Diphtheria (booster, maternal) Diphtheria antitoxin Hep B birth dose Pertussis (booster) PCV catchup IPV Tetanus toxoid (booster, maternal) Ebola (pre-emptive vaccination) Zika Norovirus ETEC HIV TB 2nd generation Chikungunya CEPI vaccines? 11

12 VIS has traditionally prioritised health impact, but opportunity to broaden investment lens Previous VIS Overall and U5 mortality Procurement cost per deaths averted Current VIS Additional lenses for health impact? Morbidity, AMR, strengthening delivery platforms Looking beyond direct health impact? Global public good vaccines (e.g., epidemics; eradication) 12

13 Should Gavi consider others investments or signalling beyond funding broad use? Global stockpile Learning agenda Signalling future priorities (vaccines in 5-10 year window) 13

14 Potentially taking a longer-term view within the VIS VIS: 5 year scope Vaccine development: 10+ years Long-term guidance within the VIS? 14

15 Questions for discussion 1. How can we align Gavi and PDVAC prioritisation of pipeline vaccines? 2. To what extent can PDVAC help guide Gavi assessment of longer term ( VIS+ ) vaccine priorities? 3. What (non-binding) guidance from Gavi would be helpful to focus vaccine R&D and how does that fit in with WHO/PDVAC work on PPCs/TPPs? 15

How does Gavi make vaccine investment decisions?

How does Gavi make vaccine investment decisions? How does Gavi make vaccine investment decisions? Judith Kallenberg Global Vaccine and Immunization Research Forum Johannesburg, South-Africa, 16 March 2016 www.gavi.org Vaccine Investment Strategy (VIS)

More information

Report to the Board 6-7 June 2018

Report to the Board 6-7 June 2018 6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment

More information

Gavi s Vaccine Investment Strategy

Gavi s Vaccine Investment Strategy Gavi s Vaccine Investment Strategy Judith Kallenberg, Head of Policy WHO Product Development for Vaccines Advisory Committee Meeting Geneva, Switzerland, 7-9 September 2015 www.gavi.org Vaccine Investment

More information

Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the global vaccine markets

Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the global vaccine markets Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the global vaccine markets Seth Berkley M.D, CEO, Seoul www.gavi.org 1 Gavi s mission, model and achievements to date Gavi s mission Saving

More information

Gavi initiatives for improving vaccine supply

Gavi initiatives for improving vaccine supply Gavi initiatives for improving vaccine supply Melissa Malhame DCVMN, 28 October 2014 A world free from vaccine preventable diseases www.gavi.org Agenda 1. Gavi Strategy 2011-2015, and supply and procurement

More information

GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS

GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing

More information

The power of partnership: the GAVI Alliance Board

The power of partnership: the GAVI Alliance Board The power of partnership: the GAVI Alliance Board 1 GAVI s mission To save children s lives and protect people s health by increasing access to immunisation in poor countries Strategic goals 2011 2015!

More information

Report to the Board 6-7 June 2018

Report to the Board 6-7 June 2018 Report to the Board 6-7 June 2018 SUBJECT: Category: PROGRAMME AND POLICY COMMITTEE CHAIR REPORT For Information Section A: Introduction This report provides the Board with an overview of the activities

More information

@GaviSeth. Report from Gavi. Seth Berkley, CEO Meeting of the Strategic Advisory Group of Experts on Immunization April

@GaviSeth. Report from Gavi. Seth Berkley, CEO Meeting of the Strategic Advisory Group of Experts on Immunization April 1 @GaviSeth Report from Gavi Seth Berkley, CEO Meeting of the Strategic Advisory Group of Experts on Immunization April 2016 www.gavi.org Why SAGE matters to Gavi Gavi relies on SAGE technical guidance

More information

Keynote Address: The Challenge of Achieving Universal Access to Vaccines

Keynote Address: The Challenge of Achieving Universal Access to Vaccines Keynote Address: The Challenge of Achieving Universal Access to Vaccines & AMF Seth Berkley M.D, CEO www.gavi.org 1 Vaccine landscape The world before vaccines Examples of major disease outbreaks Yellow

More information

The Financial Sustainability of New Vaccine Introduction in the Poorest Countries :

The Financial Sustainability of New Vaccine Introduction in the Poorest Countries : The Financial Sustainability of New Vaccine Introduction in the Poorest Countries : Evidence from the First Phase of GAVI (Global Alliance for Vaccines and Immunization) Patrick Lydon lydonp@who.int Session:

More information

Perspectives on Ensuring Access to Vaccines in Lower Income Countries

Perspectives on Ensuring Access to Vaccines in Lower Income Countries Perspectives on Ensuring Access to Vaccines in Lower Income Countries Greg Widmyer Deputy Director, Vaccine Delivery Foundation Merieux January 20, 2015 Bill & Melinda Gates Foundation BMGF GLOBAL PROGRAMS

More information

TODAY S VACCINATION ECOSYSTEM STATUS MARKET-SHAPING PRINCIPLES, PRACTICE, IMPACT AND LESSONS LEARNT GAVI PERSPECTIVE

TODAY S VACCINATION ECOSYSTEM STATUS MARKET-SHAPING PRINCIPLES, PRACTICE, IMPACT AND LESSONS LEARNT GAVI PERSPECTIVE TODAY S VACCINATION ECOSYSTEM STATUS MARKET-SHAPING PRINCIPLES, PRACTICE, IMPACT AND LESSONS LEARNT GAVI PERSPECTIVE Aurélia Nguyen Tuesday 20 January 2015, Veyrier-du-Lac, France www.gavi.org AGENDA Market

More information

Overall presentation of IVR Strategy

Overall presentation of IVR Strategy Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research

More information

Report to the. GAVI Alliance Board November 2013

Report to the. GAVI Alliance Board November 2013 Report to the GAVI Alliance Board 21-22 November 2013 Subject: Report of: Authored by: Vaccine Investment Strategy Nina Schwalbe, Managing Director, Policy and Performance Judith Kallenberg, Senior Specialist,

More information

Global Health Policy: Vaccines

Global Health Policy: Vaccines Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY

More information

Gavi s strategic framework 22 June 2016

Gavi s strategic framework 22 June 2016 Gavi s 2016 2020 strategic framework 22 June 2016 Gavi 2000-2015 Gavi 3.0 Gavi 2.0 250 million children immunised Gavi 1.0 90m children immunised 200 million children immunised 2000 2005 2006 2010 2011

More information

Vaccines. Global impact of a preventive technology. Edwin J. Asturias, MD

Vaccines. Global impact of a preventive technology. Edwin J. Asturias, MD Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public

More information

MALARIA VACCINE PILOTS

MALARIA VACCINE PILOTS MALARIA VACCINE PILOTS BOARD MEETING Judith Kallenberg, Geneva Reach every child www.gavi.org Developments since 2013 (1/5) 2013 Malaria vaccine shortlisted in Vaccine Investment Strategy Board decision

More information

Gavi Unicef Vaccine Industry Consultation. Dominic Hein Market Shaping / Gavi. October Reach every child

Gavi Unicef Vaccine Industry Consultation. Dominic Hein Market Shaping / Gavi. October Reach every child Gavi Update @ Unicef Vaccine Industry Consultation Dominic Hein Market Shaping / Gavi October 2018 Reach every child www.gavi.org Gavi commitments to countries US$ 13.67 billion committed since 2001 New

More information

Vaccines. Global impact of a preventive technology. Edwin J. Asturias, MD

Vaccines. Global impact of a preventive technology. Edwin J. Asturias, MD Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public

More information

REVIEW OF DECISIONS. BOARD MEETING 6-7 June 2018, Geneva. Reach every child

REVIEW OF DECISIONS. BOARD MEETING 6-7 June 2018, Geneva. Reach every child REVIEW OF DECISIONS BOARD MEETING, Geneva Reach every child www.gavi.org Decision 1: Consent Agenda: Vice Chair Appointment a) Reappointed William (Bill) Roedy as an Unaffiliated Board member through to

More information

GAVI Role in IPV Introductions

GAVI Role in IPV Introductions GAVI Role in IPV Introductions Melissa Malhame 12 th WHO/UNICEF Consultation with OPV/IPV Manufacturers and National Regulatory Authorities Geneva, Switzerland, 10 GAVI vaccine support Currently supported

More information

GAVI S CONTINUED ROLE IN YELLOW FEVER CONTROL

GAVI S CONTINUED ROLE IN YELLOW FEVER CONTROL GAVI S CONTINUED ROLE IN YELLOW FEVER CONTROL BOARD MEETING Michael F Thomas, Abidjan, Côte d Ivoire Reach every child www.gavi.org EVOLVING CONTEXT: THREATS AND OPPORTUNITIES Yellow fever is a global

More information

The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007

The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007 History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we

More information

Update from GAVI Aurelia Nguyen

Update from GAVI Aurelia Nguyen Update from GAVI Aurelia Nguyen (Copenhagen, Denmark, 27 June 2012) GAVI vaccine support Currently supported vaccines: pentavalent, pneumococcal, rotavirus, meningitis A, human papillomavirus (HPV), rubella,

More information

VACCINE MARKETS OVERVIEW SESSION

VACCINE MARKETS OVERVIEW SESSION VACCINE MARKETS OVERVIEW SESSION Robyn Iqbal Program Officer, Vaccine Delivery Market Dynamics UNICEF SD Manufacturers Meeting Copenhagen October 8, 2014 DRAFT Bill & Melinda Gates Foundation DISCUSSION

More information

Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer

Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer SAGE meeting Geneva, 8-10 November 2011 Topics to cover Update on new vaccine introduction Introductions New approvals Co-financing

More information

Last mile vaccine distribution to rural health centres. Faheem Merchant

Last mile vaccine distribution to rural health centres. Faheem Merchant Last mile vaccine distribution to rural health centres Faheem Merchant New Global Immunization Goals 2000 - Millennium Development Goal # 4 Reduce under 5 child mortality by 2/3 between 1990 and 2015.

More information

From development to delivery: Decision-making for the introduction of a new vaccine

From development to delivery: Decision-making for the introduction of a new vaccine From development to delivery: Decision-making for the introduction of a new vaccine Prince Mahidol Award Conference Bangkok, Thailand 1-2 February 2007 Dr. J.M. Okwo-Bele Department of Immunization, Vaccines

More information

TYPHOID CONJUGATE VACCINE SUPPORT WINDOW

TYPHOID CONJUGATE VACCINE SUPPORT WINDOW TYPHOID CONJUGATE VACCINE SUPPORT WINDOW BOARD MEETING Michael F Thomas 29-30 November 2017, Vientiane, Lao PDR Reach every child www.gavi.org Agenda 1 2 3 4 5 Why TCVs? Historical decisions and update

More information

Challenges of use of cholera vaccines in Haiti and the Americas

Challenges of use of cholera vaccines in Haiti and the Americas http://www.paho.org Challenges of use of cholera vaccines in Haiti and the Americas Dr. Cuauhtémoc Ruiz Matus Comprehensive Family Immunization Program Background Topics Consultations at PAHO Challenges

More information

History and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8

History and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop

More information

Update on Transition: the case of Honduras. Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016

Update on Transition: the case of Honduras. Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016 Update on Transition: the case of Honduras Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016 GAVI Support for Honduras Content Honduras EPI Situation 2011-2016 Vaccination

More information

Gavi Alliance Strategy : Goal level indicators and disease dashboard

Gavi Alliance Strategy : Goal level indicators and disease dashboard Gavi Alliance Strategy 2016-2020: Goal level indicators and disease dashboard BOARD MEETING Peter Hansen and Hope Johnson 10-11 June 2015, Geneva Reach every child www.gavi.org Strategic enablers Goal-level

More information

Vaccine Innovation and Adult Immunization Landscape

Vaccine Innovation and Adult Immunization Landscape Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org

More information

Economics of Vaccine Development A Vaccine Manufacturer s Perspective

Economics of Vaccine Development A Vaccine Manufacturer s Perspective Economics of Vaccine Development A Vaccine Manufacturer s Perspective Gerald Voss The Value of Vaccines 2 29 diseases are currently preventable by vaccination Global public health Cervical cancer 1 Diphtheria

More information

Yellow fever Vaccine investment strategy

Yellow fever Vaccine investment strategy Yellow fever Vaccine investment strategy Background document #5 November 2013 Executive summary Since 2001, GAVI has spent ~$250M on yellow fever control $102M on routine vaccination in 17 countries ~$160M

More information

Report to the Board. Typhoid vaccines: WHO Position paper. Weekly epidemiological record. 2008; 6: ibid

Report to the Board. Typhoid vaccines: WHO Position paper. Weekly epidemiological record. 2008; 6: ibid Annex B: Background and Overview of Analyses Gavi s Historical Decisions on TCV In the 2008 VIS, the Board prioritised TCVs for Gavi s portfolio along with Rubella, HPV, and JE vaccines. Although no financial

More information

VERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance

VERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance Version No.: 1.0 Page 1 / 5 DOCUMENT ADMINISTRATION VERSION APPROVAL PROCESS DATE NUMBER 1.0 Nina Schwalbe, Managing Director, and Performance Reviewed by: GAVI Programme 23 April 2012 and Committee Approved

More information

HPV Vaccine Lessons Learned & New Ways Forward

HPV Vaccine Lessons Learned & New Ways Forward HPV Vaccine Lessons Learned & New Ways Forward The Gavi Alliance June 2016, Geneva www.gavi.org Overview 1 Background 2 Lessons learned 3 New Way Forward 2 1 Background 3 HPV Background HPV is responsible

More information

SUCCESSFULLY TRANSITIONING NIGERIA FROM GAVI SUPPORT

SUCCESSFULLY TRANSITIONING NIGERIA FROM GAVI SUPPORT SUCCESSFULLY TRANSITIONING NIGERIA FROM GAVI SUPPORT BOARD MEETING Pascal Bijleveld, Nadia Lasri, Geneva, Switzerland Reach every child www.gavi.org Key developments since the last No immediate change

More information

GAVI 5.0 THE ALLIANCE S STRATEGY

GAVI 5.0 THE ALLIANCE S STRATEGY GAVI 5.0 THE ALLIANCE S 2021-25 STRATEGY BOARD MEETING Seth Berkley 28-29 November 2018, Geneva, Switzerland Reach every child www.gavi.org As the world moves from MDGs into SDGs, Gavi 5.0 is an opportunity

More information

IMPORTANCE OF VACCINE PREVENTABLE DISEASE INCIDENCE. Bradford D. Gessner, MD Agence de Médecine Preventive

IMPORTANCE OF VACCINE PREVENTABLE DISEASE INCIDENCE. Bradford D. Gessner, MD Agence de Médecine Preventive IMPORTANCE OF VACCINE PREVENTABLE DISEASE INCIDENCE Bradford D. Gessner, MD Agence de Médecine Preventive Vaccine Launches 2013 2 Disease burden has been consistently mentioned by policymakers in countries

More information

GAVI, THE VACCINE ALLIANCE

GAVI, THE VACCINE ALLIANCE #vaccineswork GAVI, THE VACCINE ALLIANCE Natasha Bilimoria December 2016 National Academy of Sciences www.gavi.org 1 ABOUT GAVI Gavi s mission: to save children s lives and protect people s health by increasing

More information

DCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014.

DCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. DCVMN AND VACCINE SECURITY IN ASEAN REGION ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. Phuket - Thailand Developing Countries Vaccine Manufacturers Network (DCVMN)

More information

Access to vaccination in GAVI countries and at global level

Access to vaccination in GAVI countries and at global level Access to vaccination in GAVI countries and at global level Stefano Malvolti Director, Vaccine Implementation GAVI Alliance 15th ADVANCED COURSE OF VACCINOLOGY May 12, 2014 Global progress to MDG 4 for

More information

Gavi Secretariat Update: Progress, priorities and strategies

Gavi Secretariat Update: Progress, priorities and strategies Gavi Secretariat Update: Progress, priorities and strategies Melissa Malhame UNICEF Vaccine Manufacturer Consultation Copenhagen 8-9 October 2014 www.gavi.org Gavi s impact 2000-2013 2 New vaccines now

More information

Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework

Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework I. Purpose This Framework sets out the principles and several essential requirements for Gavi s Health

More information

1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector

1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector 1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share

More information

Global Health Policy: Vaccines

Global Health Policy: Vaccines Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY

More information

Product Development for Vaccines Advisory Committee:

Product Development for Vaccines Advisory Committee: Product Development for Vaccines Advisory Committee: Highlights from the 2016 year of vaccine development SAGE, October 2016 David C. Kaslow, MD Chair, Product Development for Vaccines Advisory Committee

More information

Vaccines on the Global Scale

Vaccines on the Global Scale Vaccines on the Global Scale Learning from the past and aiming at the future Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health,

More information

Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines

Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines 1 Vaccines: the single most effective medical intervention 2 Vaccines save lives Millions of cases

More information

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020. Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy

More information

GAVI Secretariat response to the IFFIm evaluation

GAVI Secretariat response to the IFFIm evaluation GAVI Secretariat response to the IFFIm evaluation Introduction The terms of reference of the IFFIm evaluation called for an assessment both of IFFIm s efficacy as a financing mechanism, as well as the

More information

GAVI Alliance Demand-side Innovation Policies

GAVI Alliance Demand-side Innovation Policies GAVI Alliance Demand-side Innovation Policies Presentation at the Multi-year Expert Meeting on Investment, Innovation and Entrepreneurship for Productive Capacity-building and Sustainable Development Lauren

More information

Outline. Role of Developing Country Vaccine Industry For Meeting Global Vaccine Needs. Immunization Landscape ADVAC 2013

Outline. Role of Developing Country Vaccine Industry For Meeting Global Vaccine Needs. Immunization Landscape ADVAC 2013 Role of Developing Country Vaccine Industry For Meeting Global Vaccine Needs ADVAC 2013 Dr. Suresh Jadhav Executive Director Serum Institute of Limited Maharashtra,, 411028 ssj@seruminstitute.com France,

More information

Adolescent vaccination strategies

Adolescent vaccination strategies Adolescent vaccination strategies Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases & Molecular Medicine University of Cape Town www.vacfa.uct.ac.za gregory.hussey@uct.ac.za

More information

Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women

Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women Estimating the full public health value of vaccines Kathleen M. Neuzil, MD, MPH Professor of Medicine

More information

USAID Progress: The U.S. National Vaccine Plan of 1994

USAID Progress: The U.S. National Vaccine Plan of 1994 USAID Progress: The U.S. National Vaccine Plan of 1994 Ellyn Ogden Neal Brandes Angela Weaver Washington DC March 3, 2008 Objective 1.1/1.5 (New Vaccines) Support to GAVI for introduction of new vaccines

More information

For Health Worldwide Financing Gavi, the Vaccine Alliance as an investment in the future

For Health Worldwide Financing Gavi, the Vaccine Alliance as an investment in the future For Health Worldwide Financing Gavi, the Vaccine Alliance as an investment in the future 2 Immunisation is one of the most costeffective and impactful investments we can make to improve the health of children

More information

Copyright regulations Warning

Copyright regulations Warning COMMONWEALTH OF AUSTRALIA Copyright regulations 1969 Warning This material has been reproduced and communicated to you by or on behalf of the University of Melbourne pursuant to part VB of the Copyright

More information

Dr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya

Dr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya Dr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya Presentation Outline Background Immunization Performance review Available Opportunities for engagement Planned and ongoing strategies- New

More information

Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) October 20-22, 2015 Conclusions and Recommendations

Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) October 20-22, 2015 Conclusions and Recommendations Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) October 20-22, 2015 Conclusions and Recommendations Published in the Weekly Epidemiological Record on 11 December, 2015 http://

More information

Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG)

Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG) Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG) Background India was certified polio-free along with 10 other countries of WHO South-East Asia Region

More information

Thailand Expanded Program on Immunization. Suchada Jiamsiri, MD, MPH Division of Vaccine Preventable Diseases Ministry of Public Health, Thailand

Thailand Expanded Program on Immunization. Suchada Jiamsiri, MD, MPH Division of Vaccine Preventable Diseases Ministry of Public Health, Thailand Thailand Expanded Program on Immunization Suchada Jiamsiri, MD, MPH Division of Vaccine Preventable Diseases Ministry of Public Health, Thailand Outline Expanded Program on Immunization Organization Immunization

More information

Global Report to SAGE. Fulfillment of previous recommendations & progress highlights

Global Report to SAGE. Fulfillment of previous recommendations & progress highlights Global Report to SAGE Fulfillment of previous recommendations & progress highlights SAGE Meeting, 8-10 November 2012 J.M. Okwo-Bele, WHO Outline 1 2 3 4 Global progress Regional updates- RTAGs recommendations

More information

Gavi s private sector engagement approach

Gavi s private sector engagement approach Gavi s 2016-2020 private sector engagement approach SCALING INNOVATION FOR IMPACT Gavi Board technical briefing session 21 June 2016 Geneva, Switzerland Reaching further, together www.gavi.org A HISTORY

More information

CHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES

CHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES CHAPTER ONE: EXECUTIVE SUMMARY The Global Vaccine Industry o Scope and Methodology o Overview o Pediatric Preventative Vaccines o The Market o Adult Preventative Vaccines o The Market o Total Market o

More information

UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013

UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013 UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013 Presentation overview Scope of UNICEF procurement Overview of UNICEF procurement Vaccine market updates UNICEF procures

More information

Gavi, the Vaccine Alliance: Supply and Procurement Strategy

Gavi, the Vaccine Alliance: Supply and Procurement Strategy Gavi, the Vaccine Alliance: Supply and Procurement Strategy 2016-20 Executive Summary Four strategic goals guide the mission of Gavi, the Vaccine Alliance. Its fourth strategic goal (SG4) is to shape markets

More information

Introduction of new vaccines: public health - policy decisions and programmatic implications

Introduction of new vaccines: public health - policy decisions and programmatic implications Network for Education and Support in Immunisation Introduction of new vaccines: public health - policy decisions and programmatic implications André Meheus & Fred van der Veen SAVIC-Gauteng 2009 EPI symposium

More information

Immunization Update & focus on meningococcal vaccine PART 1

Immunization Update & focus on meningococcal vaccine PART 1 Immunization Update & focus on meningococcal vaccine PART 1 Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases University of Cape Town www.vacfa.uct.ac.za Disclosures Received

More information

Summary of Definitions of Mission and Strategic Goal Level Indicators. in GAVI Alliance Strategy Updated October 2013

Summary of Definitions of Mission and Strategic Goal Level Indicators. in GAVI Alliance Strategy Updated October 2013 Summary of s of Mission and Strategic Goal Level Indicators in GAVI Alliance Strategy 2011-2015 Updated October 2013 Table of Contents Under five mortality rate ------------------------------------------------------------------------------------------------------------------------

More information

2016/17 Vaccination and Immunisation list of additional services and enhanced services

2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:

More information

Table Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines

Table Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines Table Of Contents Executive Summary THE GLOBAL VACCINES INDUSTRY Scope and Methodology Overview Pediatric Preventative Vaccines THE MARKET Adult Preventative Vaccines THE MARKET TOTAL MARKET ISSUES AND

More information

2017/18 Immunisation programmes list of additional and enhanced services

2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2017 Prepared

More information

Base Demand Forecast. v15, prepared in Reach every child

Base Demand Forecast. v15, prepared in Reach every child Base Demand Forecast v15, prepared in 2017 Reach every child www.gavi.org December, 2017 Introduction This is the second publication of the Base Demand Forecast that describes the volume projections that

More information

2018/19 Immunisation programmes list of additional and enhanced services

2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2018 Prepared

More information

UPDATE FROM GAVI, THE VACCINE ALLIANCE

UPDATE FROM GAVI, THE VACCINE ALLIANCE UPDATE FROM GAVI, THE VACCINE ALLIANCE MEETING Dr. Seth Berkley, CEO www.gavi.org Gavi and as Gavi s technical body Gavi s support for 2030 agenda is a critical partner for the Gavi Alliance Ø Gavi relies

More information

GSK VACCINES: KEY GROWTH DRIVERS

GSK VACCINES: KEY GROWTH DRIVERS GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre of Excellence, GSK Biologicals Millions of children die from infectious diseases Many of these deaths are preventable

More information

Vaccines: Poised To Deliver Significant Growth in Emerging Markets

Vaccines: Poised To Deliver Significant Growth in Emerging Markets Vaccines: Poised To Deliver Significant Growth in Emerging Markets 4 th DVFA Symposium Life Science Pierre Morgon Vice-President, Franchise & Global Marketing Operations, Sanofi Pasteur Frankfurt, May

More information

Sustaining Immunization in Developing Countries: The Future We Make

Sustaining Immunization in Developing Countries: The Future We Make Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication

More information

Establishing a second-year-of-life (2YL) healthy child visit

Establishing a second-year-of-life (2YL) healthy child visit Establishing a second-year-of-life (2YL) healthy child visit Dr Rudi Eggers Presentation to the Global Vaccines and Immunization Research Forum Sandton, 15 March 2016 Session Objectives Provide an overview

More information

Improving the vaccine supply chain in developing countries via increasing freeze protected cold chain equipment. October, 2014

Improving the vaccine supply chain in developing countries via increasing freeze protected cold chain equipment. October, 2014 Improving the vaccine supply chain in developing countries via increasing freeze protected cold chain equipment October, 2014 CHAI s mission is to save lives by increasing access to health commodities

More information

PRINCIPLES OF VACCINE PORTFOLIO PRIORITIZATION AND MANAGEMENT

PRINCIPLES OF VACCINE PORTFOLIO PRIORITIZATION AND MANAGEMENT PRINCIPLES OF VACCINE PORTFOLIO PRIORITIZATION AND MANAGEMENT Product Development Boot Camp November 5, 2015 New York, New York 2014 Bill & Melinda Gates Foundation Global Program Organization Global Health

More information

Programme Bulletin Policy updates and vaccine information for GAVI countries and partners

Programme Bulletin Policy updates and vaccine information for GAVI countries and partners Programme Bulletin Policy updates and vaccine information for GAVI countries and partners July 2013 Welcome! Welcome to the first edition of the GAVI Alliance Programme Bulletin, a new information resource

More information

Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision

Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data received

More information

GAVI, THE VACCINE ALLIANCE

GAVI, THE VACCINE ALLIANCE #vaccineswork GAVI, THE VACCINE ALLIANCE Partnerships for Health Outcomes Susan Brown July, 2017, New York Gavi/2012/Doune Porter www.gavi.org 1 ABOUT GAVI Gavi s mission: to save children s lives and

More information

Immunizations are among the most cost effective and widely used public health interventions.

Immunizations are among the most cost effective and widely used public health interventions. Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean

More information

Overview of Measlescontaining. through UNICEF. Overview of [VACCINE] through UNICEF

Overview of Measlescontaining. through UNICEF. Overview of [VACCINE] through UNICEF Overview of Measlescontaining vaccines through UNICEF Overview of [VACCINE] through UNICEF Children wait to be immunized against measles and rubella at the Losikito primary school in Tanzania. Source:

More information

GAVI Alliance. Aurelia Nguyen, Director Policy & Market Shaping. IPC Meeting 30 May 2013

GAVI Alliance. Aurelia Nguyen, Director Policy & Market Shaping. IPC Meeting 30 May 2013 GAVI Alliance Aurelia Nguyen, Director Policy & Market Shaping IPC Meeting 30 May 2013 GAVI Update GAVI Alliance Overview 4 Strategic Goals 3 Market Shaping Objectives GAVI Supported Vaccines Critical

More information

IVI STRATEGY ARTICULATION. October 12, 2015

IVI STRATEGY ARTICULATION. October 12, 2015 IVI STRATEGY ARTICULATION October 12, 2015 Overall messages for today Our Vision and Mission are as relevant today as they have ever been We need to focus on the diseases and activities where we can have

More information

Global Vaccine Market Report

Global Vaccine Market Report Global Vaccine Market Report Executive Summary In response to repeated calls from WHO Member States, WHO launched the Market Information for Access to Vaccines (MI4A) initiative to enhance vaccine market

More information

Polio and routine immunisation Alan Brooks

Polio and routine immunisation Alan Brooks Polio and routine immunisation Alan Brooks Geneva, Switzerland, Background 1 History of polio eradication World Health Assembly Resolution 400 Previous eradication targets Polio cases (thousands) 300 200

More information

VACCINES TRIUMPHS AND TRIBULATIONS. William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine

VACCINES TRIUMPHS AND TRIBULATIONS. William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine VACCINES TRIUMPHS AND TRIBULATIONS William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine Never in the history of human progress has a better and cheaper

More information

Role of Partnerships in Developing Innovative Vaccines: Brazil

Role of Partnerships in Developing Innovative Vaccines: Brazil Role of Partnerships in Developing Innovative Vaccines: Brazil SAGE Meeting, October 2010 Reinaldo Guimarães, M.D, MSc. Secretary of Science, Technology and Strategic Inputs Ministry of Health of Brazil

More information

Meeting Nigeria s vaccines financing needs ( )

Meeting Nigeria s vaccines financing needs ( ) Meeting Nigeria s vaccines financing needs (2016-2025) Inter-ministerial meeting discussion document April 2016 Objectives of today s inter-ministerial meeting Share the context of immunization financing

More information

Partnerships for Vaccines Forum

Partnerships for Vaccines Forum October 30, 2018 Partnerships for Vaccines Forum PATH s 40+ years of transformative innovation Steve Davis President & CEO, PATH Photos: PATH/Aaron Joel Santos, PATH/Gabe Bienczycki, PATH/Gabe Bienczycki

More information